SCHEMBL13334827

SCHEMBL13334827

C#C[C@@]1(CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 5/20 0.70
▸ LMNA P02545 5/20 0.70
▸ ABCB11 O95342 4/20 0.70
▸ PGR P06401 4/20 0.70
▸ SLC6A4 P31645 3/20 0.70
▸ CYP2C19 P33261 3/20 0.70
▸ NR3C1 P04150 3/20 0.70
▸ ESR1 P03372 2/20 0.70
▸ SHBG P04278 2/20 0.70
▸ TSHR P16473 1/20 0.70
▸ HIF1A Q16665 1/20 0.70
▸ ALDH1A1 P00352 1/20 0.70
▸ ADRA2A P08913 1/20 0.70
▸ MEN1 O00255 3/20 0.63
▸ KMT2A Q03164 3/20 0.63
▸ AR P10275 3/20 0.63
▸ POLB P06746 1/20 0.63
▸ MAPT P10636 2/20 0.63
▸ CHRM2 P08172 1/20 0.63
▸ ADORA3 P0DMS8 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4216594 0.89 CYP3A4 (0.61) CYP3A4LMNAABCB11PGRSLC6A4
SCHEMBL24476297 0.89 CYP3A4 (0.69) CYP3A4LMNAABCB11PGRSLC6A4
SCHEMBL24476299 0.88 CYP3A4 (0.68) CYP3A4LMNAABCB11PGRSLC6A4
SCHEMBL13473537 0.87 PGR (0.76) CYP3A4LMNAABCB11PGRSLC6A4
SCHEMBL24476413 0.86 CYP3A4 (0.66) CYP3A4LMNAABCB11PGRSLC6A4
Norethindrone SCHEMBL24476231 0.82 CYP3A4 (1.00) CYP3A4LMNAABCB11PGRSLC6A4
Norethindrone SCHEMBL7768886 0.82 CYP3A4 (1.00) CYP3A4LMNAABCB11PGRSLC6A4
Norethindrone SCHEMBL23390 0.82 CYP3A4 (1.00) CYP3A4LMNAABCB11PGRSLC6A4
Norethindrone SCHEMBL14074493 0.82 CYP3A4 (1.00) CYP3A4LMNAABCB11PGRSLC6A4
Norethindrone SCHEMBL6834811 0.82 CYP3A4 (1.00) CYP3A4LMNAABCB11PGRSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010066355-A1 USE OF 17β-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR MANUFACTURING A MEDICAMENT IN A SUSTAINED-RELEASE FORM FOR PARENTERAL USE, AND SUSTAINED-RELEASE MEDICAMENT CONTAINING 17β-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR PARENTERAL USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-17 — — WO disclosed
WO-2008151746-A2 17β-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-18 — — WO disclosed
Send feedback